Brian Leyland‐Jones

32.1k total citations · 5 hit papers
218 papers, 18.4k citations indexed

About

Brian Leyland‐Jones is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Brian Leyland‐Jones has authored 218 papers receiving a total of 18.4k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 82 papers in Molecular Biology and 61 papers in Cancer Research. Recurrent topics in Brian Leyland‐Jones's work include HER2/EGFR in Cancer Research (50 papers), Cancer Treatment and Pharmacology (29 papers) and Cancer Genomics and Diagnostics (28 papers). Brian Leyland‐Jones is often cited by papers focused on HER2/EGFR in Cancer Research (50 papers), Cancer Treatment and Pharmacology (29 papers) and Cancer Genomics and Diagnostics (28 papers). Brian Leyland‐Jones collaborates with scholars based in United States, Canada and Italy. Brian Leyland‐Jones's co-authors include Dennis J. Slamon, José Baselga, Mark D. Pegram, Virginia Paton, W. Eiermann, Alex Bajamonde, Steven Shak, Janet Wolter, Thomas Fleming and Larry Norton and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Brian Leyland‐Jones

214 papers receiving 17.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 8.4k citations Brian Leyland‐Jones, José Baselga et al. profile →
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

2017 688 citations David Cameron, Martine Piccart et al. The Lancet profile →
Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

2005 505 citations Brian Leyland‐Jones, José Baselga et al. Journal of Clinical Oncology profile →
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500

2014 482 citations Brian Leyland‐Jones et al. Journal of Clinical Oncology profile →
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

2019 429 citations Shumei Kato, Casey Williams et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Leyland‐Jones United States	53	11.6k	5.7k	4.6k	4.1k	3.3k	218	18.4k
William Novotny United States	38	12.5k 1.1×	8.0k 1.4×	3.8k 0.8×	2.6k 0.6×	5.7k 1.7×	110	22.6k
Mark D. Pegram United States	56	17.8k 1.5×	6.8k 1.2×	4.9k 1.1×	8.5k 2.0×	4.6k 1.4×	221	23.8k
John Crown Ireland	71	13.0k 1.1×	7.4k 1.3×	6.0k 1.3×	2.4k 0.6×	4.8k 1.4×	416	20.1k
P. Fumoleau France	61	9.6k 0.8×	3.3k 0.6×	4.4k 0.9×	2.3k 0.5×	2.7k 0.8×	326	14.3k
Sandra M. Swain United States	66	15.4k 1.3×	5.1k 0.9×	7.2k 1.6×	4.9k 1.2×	4.8k 1.4×	337	23.4k
Luca Gianni Italy	72	20.5k 1.8×	8.2k 1.4×	8.3k 1.8×	5.7k 1.4×	6.0k 1.8×	309	30.7k
Allan T. van Oosterom Belgium	32	9.3k 0.8×	4.5k 0.8×	2.8k 0.6×	2.4k 0.6×	10.1k 3.1×	89	21.9k
Michaele C. Christian United States	28	9.4k 0.8×	3.6k 0.6×	2.7k 0.6×	2.5k 0.6×	6.9k 2.1×	48	18.5k
Eric K. Rowinsky United States	81	18.5k 1.6×	12.1k 2.1×	3.6k 0.8×	2.1k 0.5×	9.6k 2.9×	396	32.1k
Lyndsay N. Harris United States	53	9.3k 0.8×	5.1k 0.9×	5.5k 1.2×	3.0k 0.7×	2.9k 0.9×	192	15.0k

Countries citing papers authored by Brian Leyland‐Jones

Since Specialization

Citations

This map shows the geographic impact of Brian Leyland‐Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Leyland‐Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Leyland‐Jones more than expected).

Fields of papers citing papers by Brian Leyland‐Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Leyland‐Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Leyland‐Jones. The network helps show where Brian Leyland‐Jones may publish in the future.

Co-authorship network of co-authors of Brian Leyland‐Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Leyland‐Jones. A scholar is included among the top collaborators of Brian Leyland‐Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Leyland‐Jones. Brian Leyland‐Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Filipits, Martin, Urania Dafni, Michael Gnant, et al.. (2018). Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Clinical Cancer Research. 24(13). 3079–3086. 15 indexed citations

Cameron, David, Martine Piccart, Richard D. Gelber, et al.. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet. 389(10075). 1195–1205. 688 indexed citations breakdown →

Kato, Shumei, Nithya Krishnamurthy, Kimberly C. Banks, et al.. (2017). Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Research. 77(16). 4238–4246. 90 indexed citations

Loi, Sherene, Urania Dafni, Dimitris Karlis, et al.. (2016). Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. JAMA Oncology. 2(8). 1040–1040. 65 indexed citations

Aapro, Matti, Volker Moebus, Ulrike Nitz, et al.. (2014). Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. Annals of Oncology. 26(4). 688–695. 21 indexed citations

Sun, Yuliang, Nandini Dey, Melissa Brammer, Pradip De, & Brian Leyland‐Jones. (2013). Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model. Cancer Chemotherapy and Pharmacology. 72(4). 733–745. 8 indexed citations

Metzger, Otto, Marion Procter, Evandro de Azambuja, et al.. (2013). Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. Journal of Clinical Oncology. 31(16). 1954–1960. 30 indexed citations

Leyland‐Jones, Brian & Brian R. Smith. (2011). Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. The Lancet Oncology. 12(3). 286–295. 52 indexed citations

Long, Qi, Brent A. Johnson, Adeboye O. Osunkoya, et al.. (2011). Protein-Coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy. American Journal Of Pathology. 179(1). 46–54. 74 indexed citations

10.

Nakanishi, Takeo, Saranya Chumsri, Nazanin Khakpour, et al.. (2010). Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. British Journal of Cancer. 102(5). 815–826. 77 indexed citations

11.

Leyland‐Jones, Brian. (2009). Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases. Journal of Clinical Oncology. 27(31). 5278–5286. 179 indexed citations

12.

Dawood, Shaheenah & Brian Leyland‐Jones. (2009). Pharmacology and Pharmacogenetics of Chemotherapeutic Agents. Cancer Investigation. 27(5). 482–488. 18 indexed citations

13.

Pagé, Viviane, et al.. (2008). Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Hormone & IGF Research. 18(6). 487–496. 45 indexed citations

14.

Stone, Erica L., Michele Vítolo, Kurt Bachman, et al.. (2006). Response of breast cancer cell lines to aminoflavone (NSC 686288) is associated with histone H2AX phosphorylation and estrogen receptor expression. Cancer Research. 66. 132–132. 4 indexed citations

15.

Audet, Robert M., et al.. (2006). Mammalian Target of Rapamycin Inhibition Synergistically Increases Cytotoxicity of Vinorelbine in Breast Cancer Cells.. Cancer Research. 66. 1192–1193. 1 indexed citations

16.

Yu, Qingnan, Elena V. Batrakova, Lori Jerome, et al.. (2004). Reversal of multidrug resistance by Pluronic block copolymers correlates with inhibition of drug efflux transporters and depletion of intracellular ATP and GSH levels.. Cancer Research. 64. 492–492. 1 indexed citations

17.

Leyland‐Jones, Brian. (2004). Treating cancer-related hypercalcemia with gallium nitrate.. PubMed. 2(6). 509–16. 14 indexed citations

18.

Leyland‐Jones, Brian. (2001). Maximizing the response to Herceptin® therapy through optimal use and patient selection. Anti-Cancer Drugs. 12. S11–S17. 14 indexed citations

19.

Leyland‐Jones, Brian & I E Smith. (2001). Role of Herceptin<sup>®</sup> in Primary Breast Cancer: Views from North America and Europe. Oncology. 61(Suppl. 2). 83–91. 17 indexed citations

20.

Gold, Jonathan, Brian Leyland‐Jones, Carlos Urmacher, & Donald Armstrong. (1983). PULMONARY AND NEUROLOGIC COMPLICATIONS OF TREATMENT WITH FIAC (2'FLUORO-5-IODO-ARACYTOSINE) IN PATIENTS WITH ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS). PubMed. 1(4). 243–252. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact